Genocea is a biopharmaceutical company headquartered in Cambridge, Massachusetts that was founded by Lux and spun-out from Harvard Medical School in 2006.
Genocea has a proprietary technology platform, ATLAS, which mimics the human immune system. The system is used find targets for adoptive cell therapies like chimeric antigen receptor (CAR-Ts) where a patient’s T cells are engineered to attack certain tumor cells.
ATLAS uses human immune cells to identify relevant antigens from libraries of pathogen proteins. Hundreds of human T cells are tested with thousands of potential antigens. The platform is used to identify targets most likely to illicit an immune response.
GEN-003, GEN-004, and GEN-009
Genocea’s pipeline includes clinical-stage T cell-enabled product candidates such as GEN-003 for genital herpes, GEN-004 for pneumococcus and earlier stage programs in chlamydia, malaria and cancer immunotherapy.Genocea has a cancer vaccine candidate, GEN-009, which is in a Phase1/2a clinical trial as of January 2019 with estimated completion in 2022.
Boston Children's Hospital
Genocea has been partnered with Richard Malley, MD, at Boston Children’s Hospital since 2008. Together they are working on a vaccine for pneumococcal infections such as pneumonia and meningitis.ATLAS was developed by Dr. Darren Higgins at Harvard University.
Dosing underway in Phase 1/2a study of Genocea's cancer vaccine candidate GEN-009; shares up 22%
SA Editor Douglas W. House
Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009
Genocea Biosciences, Inc.
Documentaries, videos and podcasts
- BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.